MANTECH Publications

Journal of Pharmacovigilance and Quality Assurance
Volume 3, Issue 2, July-December, 2021

Quality by Design

Vishal Baman[1], Shivani Kshatriya[2], Heena Ninama[3], Mitali Dalwadi[4], Dr. Umesh Upadhyay[5]

Students[1, 2, 3], Assistant Professor[4], Principle[5]

Department of Quality Assurance[1, 2, 3],DEPT. of Pharmacy

Sigma Institute of Pharmacy, Bakrol, Vadodara-390019 (Gujarat, India)

Corresponding Author's E-mail: *ninamahina28@gmail.com[3]*

Abstract

Quality by Design is the current method for best of pharmaceuticals. This paper gives concept approximately the Pharmaceutical Quality by Design (QbD). The Quality by Design is defined and a number of its factors recognized. Process parameters and best attributes are diagnosed for every unit operation. Benefits, possibilities and steps concerned in Quality by Design of Pharmaceutical products are defined. The purpose of the pharmaceutical improvement is to layout a great product and its production method to constantly supply the supposed overall performance of the product. Quality can't be examined into products however quality has to be built in by layout. It consists of the Quality target product profile, crucial quality attributes and key elements of Quality by Design. It additionally gives evaluation among product quality by end product checking out and product quality through Quality by Design. The basis of Quality by Design is ICH Guidelines. It is primarily based totally on the ICH Guidelines.

Q8 for pharmaceutical improvement,

Q9 for quality risk management,

Q10 for pharmaceutical quality systems. It additionally offers application of Quality by Design in pharmaceutical improvement and production of pharmaceuticals.

Keywords: *Quality by Design, Process Analytical Technology, Quality target product profile, Critical Quality Attributes*

INTRODUCTION

The purpose of pharmaceutical improvement is to layout a quality product and its production method to constantly supply the meant overall performance of the product. The facts and information received from pharmaceutical improvement research and production experience offer scientific information to help the established order of the layout space, specifications, and production controls. Information from pharmaceutical improvement studies may be a basis for quality risk control. It is critical to understand that quality can't be examined into products; i.e., quality has to be built in through layout. Changes in method and production methods throughout improvement and lifecycle control have to be appeared upon as possibilities to benefit extra information and further support established order of the layout space. Similarly, inclusion of applicable information received from experiments giving surprising results also can be useful. Design space is proposed through the applicant and is problem to regulatory evaluation and approval. Working in the design space isn't taken into consideration as a change. Movement out of the design space is taken into consideration to be a change and would typically provoke a regulatory post approval change method.[1] In all cases, the product have to be designed to meet patients' desires and the meant product performance. Strategies for product improvement range from organisation to company and from product to product. The technique also can range and have to be mentioned withinside the submission. An applicant may select either an empirical technique or an extra systematic technique to product improvement, or a mixture of both. A extra systematic technique to improvement (additionally described as quality by design) can include, for example, incorporationof previous information, effects of research the use of layout of experiments, use of quality risk management,and use of information management (ICHQ10) during the lifecycle of the product. Such a scientific technique can enhance accomplishing the preferred quality of the product and assist the regulators to higher recognize a organization's strategy. Product and method information may be up to date with the information received over the product lifecycle

Design

1. Product is designed to fulfill patient desires and overall performance requirements.
2. Process is designed to constantly meet product great attributes.
3. Impact of beginning raw substances and method parameters on product quality is understood.
4. Critical reassets of method variability are diagnosed and controlled.
5. The method is constantly monitored and up to date to permit for constant great over time [2].

Definition [ICH Q 8(R1)]

A systematic technique to improvement that starts with predefined goals and emphasizes product and method knowledge and technique control, primarily based totally on sound technology and quality hazard management.[3]

Definition [FDA PAT Guidelines, Sept. 2004]

A system for designing, reading and controlling production via well timed measurements (i.e. throughout processing) of crucial quality and overall performance attributes of latest and in-method substances and techniques, with the purpose of making sure very last product safety. The concept of ―Quality by Design‖ (QbD) become described as an technique which covers a higher scientific information of crucial method and product qualities, designing controls and tests primarily based totally at the scientific limits of information throughout the improvement phase and the use of the information received throughout the life-cycle of the product to work on a regular improvement environment. QbD describes a pharmaceutical improvement technique regarding system design and improvement and production methods to keep the prescribed product quality. Guidelines and mathematical models are used to make sure the established order and use of the information at the subject in an impartial and integrated way. [4]

Benefits of QbD

- QbD is ideal Business
- Eliminate batch failures
- Minimize deviations and expensive investigations
- Avoid regulatory compliance problems
- Organizational studying is an investment withinside the future
- QbD is ideal Science
- Better improvement decisions

- Empowerment of technical staff

Opportunities

- Efficient, agile, flexible system
- Increase production efficiency, decrease costs and task rejections and waste.
- Build scientific information base for all products
- Better have interaction with enterprise on technology issues
- Ensure constant information
- Incorporate hazard management

STEPS INVOLVED IN QUALITY BY DESIGN PRODUCTS

1. Development of recent molecular entity

- Preclinical study
- Nonclinical study
- Clinical Study
- Scale up
- Submission for marketplace Approval

2. Manufacturing

- Design Space
- Process Analytical Technology
- Real time Quality Control
- 3. Control Strategy
- Risk primarily based totally decision
- Continuous Improvement
- Product performance

Seven steps of quality by design begin up plan

1. Hire an impartial Quality by design professional.
2. Audit your company and method with the expert carrying out a gape analysis.
3. Hold a primary quality by design workshop with all your personal.
4. Review the professional's record and recommendation.
5. Draft an implementation plan, timelines and expected costs.
6. Assign the resources (or agreement out).
7. Retain the impartial expert as your ―Project Assurance‖ advisor

Quality by design (QbD) and properly understood product and processes

- Sources of variability are explained.

- Variability is managed through the method.

- Product quality attributes may be correctly and reliably expected over the layout space established for substances used, method parameters, environmental and different conditions.

- To advantage better information of product performance over a number of material attributes, manufacturing

method options and method parameters considering suitable use of quality risk control principles.

QbD BY PHARMACEUTICALS

Even aleven though the pharmaceutical industry has attention on quality, it has didn't maintain up with different industries in terms of producing performance and productivity. [5]

Current situation withinside the Pharmaceutical Industry:

- Cost of revalidation
- Off - line evaluation for in - method - want based
- Product specifications as number one method of control
- Unpredictable Scale - up issues
- Inability to recognize failures

Systematic technique to development:

- That starts with predefined objectives
- Emphasizes products and method understanding
- Process control

QUALITY TARGET PRODUCT PROFILE

A summary of the drug improvement program described in terms of labeling principles and it specially recognition on the protection and efficacy.[6]

- Description
- Clinical Pharmacology
- Indications and Usage
- Contraindications
- Warnings
- Precautions
- Adverse Reactions
- Drug Abuse and Dependence
- Over dosage
- Dosage and Administration
- How Supplied
- Animal Pharmacology and/or Animal Toxicology
- Clinical Studies

A natural extension of Target Product Profile for product quality – Quality characteristics (attributes) that the drug product have to possess so as to reproducibly deliver the therapeutic advantage promised withinside the label manual to set up formulation method and maintain the formulation attempt focused and efficient .It facilitates identity of what's needed/important for the patient/customer withinside the Quality Target Product Profile.[7]

- Identifies risks and quality strategies to manage.
- Uses tools/enablers in an optimized fashion (including integration of QbD and biopharmaceutics)
- Generates and permits information sharing.
- An iterative, learning, life-cycle method for optimizing decision-making and the therapeutic effects for the patient benefit.

A drug product designed, advanced and manufactured in keeping with Quality Target Product Profile with specification (including dissolution/release acceptance criteria) constant with the preferred in vivo performance of the product.

CRITICAL QUALITY ATTRIBUTES

- It is important to discover the quality attributes that are crucial, i.e. the ones defining purity, efficiency and surrogate for Bioavailability Criticality etc. It is based at the effect of quality attribute/ parameter at the safety, efficacy & quality (manufacturability) of the product.
- Establish a link among CPP & CQAs: Identification of characteristic or parameters that may be used as a surrogate for scientific safety & efficacy (critical to patient).
- Manufacturability is likewise an characteristic (critical to business) this is important to quality.



- The stage of criticality may also differ for an API production method relative to a drug product production method
- API is one factor of a drug product and one step similarly away from the patient continuum of Criticality. Several stages of criticality can be used to describe more than one stages of risk.
- As characteristic or parameter boundaries technique edges of failure, the level of severely improved with the risk.[8]

CERTAIN KEY ASPECTS OF QBD [9]

The Target Product Quality Profile (TPQP) Target Product Quality Profile (TPQP) is a device for setting the strategic basis for drug improvement ——making plans with the result in mind.‖ More currently an extended use of the TPP in improvement making plans, clinical and commercial selection making, regulatory agency interactions, and risk control has began out to evolve.

Drug Substance and Excipient Properties

To continuously obtain the drug-product quality specified withinside the label, the drug substance desires to be thoroughly characterised with recognize to its physical, chemical, biological, and mechanical properties including solubility, polymorphism, stability, particle size, and flow properties.

Formulation Design and Development

Not all prototype formulations may be evaluated in human subjects, which suggest that growing sensitive in vitro dissolution techniques is important to an effective improvement program.

Manufacturing Process Design and Development

Process improvement and method design can't be separated due to the fact a components can't become a product without a prescribed method. Process layout is the preliminary level of method improvement, in which a define of the commercial production techniques is documented, such as the intended scales of production. The outline have to consist of all of the elements that want to be taken into consideration for the design of the technique, such as facility, equipment, material transfer, and production variables. Other elements to remember during process improvement are the QTPP and CQAs

Product quality by end product testing vs QbD

Comparison is shown between product qualities by end product testing vs. quality by design



Successful adoption

- Regulatory flexibility to deal with quality by design submissions
- Common file usual worldwide through regulatory agencies
- Post-approval adjustments inside pre-described design space may be carried out with regulatory flexibility
- Laws and methods in area to defend intellectual property (IP)

Designed to constantly meet preferred product quality

- Design space concept
- Experimentally described technique operating space based on scientific principles.
- Critical method parameters identified.
- Critical - effect product quality.
- Space - operating variety yielding suitable product Space.
- Critical technique parameters are constantly controlled.
- Product of method is usually preferred quality Product.
- End product checking out is probably reduced.

Designed to facilitate continuous improvement,

- Process manages strategy: control of the technique.
- Performance and continuous method improvement.

- Real-time method remarks Process improvements inside design space Knowledge builds with experience Leverage information/new technology to enhance method performance Key possibility to continuously enhance the technique. E.g. improved supply, more performance.

ICH Q8, Q9, Q10 Guidelines: [10]

THE FOUNDATION OF QbD, ICH Guidelines Q8 for Pharmaceutical improvement, Q9 for Quality Risk Management, Q10 for Quality systems are foundation of QbD

Quality through Design relative to ICH

- Concepts aligned
- Design Space - Key to understanding
- Design of Experiments (DOE)
- Quality management
- process robustness

Critical Concept: Design Space

- Multidimensional mixture with interactions Multidimensional interactions placed variables (e.g. raw material attributes) and method parameters
- Demonstrated to offer assurance of quality
- Defined through applicant and reviewed through regulator
- Defined regulator
- Once layout area is approved, regulatory post approval change requirements may be simplified approval Inside vs. outdoor layout space Inside space
- • Regulatory flexibility to perform inside the layout space Regulatory space.[11]

MERCK EXPERIENCE [12]

Development of Design Space: Science primarily based totally Product and Process Design in Development

- Enhance method information to help technology primarily based totally approach
- Drug substance properties designed for downstream production technique

Utilization of Design Space: Effective Process Control and Quality System

- Use of great monitoring throughout improvement to enhance method knowledge.

- Use technology primarily based totally manages throughout production.
- However, method control can be restricted through time wanted for biological assays.

Process Analytical Technology (PAT) is a vital part of Quality by Design

- Used in improvement to benefit method information
- Implemented in ordinary production to monitor method, manage product quality and decrease release checking out control
- PAT checking out can update extra laboratory testing.

APPLICATIONS OF QUALITY BY DESIGN (QBD)[13]

Quality by design (QbD) – a complete systematic technique to pharmaceutical improvement and production Advancement withinside the pharmaceutical improvement and production by Qbd may be defined against conventional technique.

In pharmaceutical development [14]

To layout a quality product and a production process to constantly supply the meant overall performance of the product

Aspects	Traditional	QbD
Pharmaceutical Development	Empirical	Systematic; Multivariate experiments
Manufacturing Process	Fixed	Adjustable within design space; opportunities for innovation
Process Control	In process testing for go/on-go; offline analysis wide or slow response	PAT utilized for feedback and feed forward at real time
Product Specification	Primary means of quality control; based on batch data	Part of the overall control strategy, based on the desired product performance
Control Strategy	Mainly by intermediate product and end product testing	Risk based; controlled shifted up stream, real time release
Lifecycle Management	Reactive time problem and OOS; Post approval changes needed	Continual improvement enabled within design space

QbD in CMC Review Offices [15]

- Science-primarily based totally assessment
- Restructured company and reorganized personnel –premarket personnel and postmarket
- CMC Pilot
- A quantity of applications submitted
- Lessons learned
- Evaluation of information
- Implementation of PMP

Office of New Drug Quality Assessment (ONDQA)[16]

- Science-primarily based totally assessment
- Restructured agency and reorganized staff –premarket personnel and post market
- CMC Pilot
- A variety of applications submitted
- Lessons learned
- Evaluation of information
- Implementation of PMP

Office of Generic Drugs (OGD)[17]

- QbR consists of the critical scientific and regulatory overview questions
- Evaluate whether or not a product is of excessive quality
- Determine the extent of risk related to the manufacture and layout of this product.
- 416 applications obtained the use of QbR through June 2007
- Successful in making sure that questions address issues concerning QbD
- Office of Biotechnology Products
- Have extra complicated products
- Already performing some factors of QbD
- In method of making ready to just accept applications the use of QbD
- Beginning a pilot for biotech products for QbD –the use of Specially comparability protocols
- Also enforcing Q8, Q9 and Q10

Benefits of Implementing QbD For FDA [18]

- Enhances scientific basis for overview Provides for higher coordination throughout review, compliance and inspection
- Improves records in regulatory submissions
- Provides for higher consistency
- Improves quality of review (organising a QMS for CMC)
- Provides for extra flexibility in decision making

- Ensures selections made on technology and now no longer on empirical facts Involves various disciplines in choice making
- Uses sources to deal with better risks

Benefits to Industry [19]

- Ensures higher design of products with much less problems in production
- Reduces quantity of producing supplements required for post market changes –rely upon method and risk information and risk mitigation
- Allows for implementation of latest generation to enhance production without regulatory scrutiny
- Allows for viable reduction in common costs of production –less waste
- Ensures fewer problems throughout review –reduced deficiencies –faster approvals.

Pharmaceutical Development [20]

Widely used in pharmaceutical development and Manufacturing.

Used in PAT

A system for designing, studying and controlling production via well timed measurement of important quality overall performance attributes of raw and in method materials and techniques with the purpose of making sure final product quality.



For experimental design [21]

A established organized technique for determining the relationship among elements affecting a technique and the output of that method Design Space Multidimensional mixture of and interaction of input variables and method parameters which have been proven to provide Quality Assurance Linkage among method inputs (inputs variables and method parameters) and important quality attributes

- Proposed through Applicant
- Subject to regulatory assessment and approval
- implementation earlier than or after MA
- Established for one or extra unit operation(s) or up to entire procedure

Quality by design technique in coating method [22]

Quality can't be examined into product however it has to be built in product. Parameters that have an effect on the coating method are given below.



Quality target product profile for the ANDA product [23]

The Quality Target Product Profile (QTPP) is ―a potential precise of the quality characteristics of a drug product that preferably can be carried out to make sure the preferred quality, considering safety and efficacy of the drug product.‖1 The QTPP is an critical element of a QbD technique and forms the premise of design for the improvement of the product. For ANDAs, the target Have to be described early in improvement primarily based totally on the properties of the drug substance (DS), characterization of the

RLD product and consideration of the RLD label and supposed patient population. By starting with the result in mind, the end result of improvement is a strong formulation and production method with a suitable control method that ensures the overall performance of the drug product. A crucial quality attribute (CQA) is ―a physical, chemical, biological, or microbiological property or characteristic that have to be inside the proper limit, range, or distribution to make sure the preferred product quality.‖1 The identity of a CQA from the QTPP is primarily based totally on the severity of damage to a patient have to the product fall outside the ideal variety for that attribute. All quality attributes are target factors of the drug product and have to be done via a great quality management system, suitable method/process design and development. From the angle of pharmaceutical development, we simplest check out the subset of CQAs of the drug product that still have a high ability to be impacted through the components or process variables. Our research culminates in the proper control strategy.

CONCLUSION

The purpose of a well-characterised technique improvement attempt is to increase a dependable technique that may be tested with a high degree of assurance to constantly produce information meeting predefined criteria while operated inside described boundaries. QbD may be carried out to the improvement and assessment of analytical techniques.

During method improvement, all capability elements (the inputs) and all important analytical responses (the outputs) are studied to decide the relationships. Critical analytical elements are recognized in an method that parallels what's defined for method improvement in ICH Q8 and Q9. The QbD method on an energetic partnership of analytical scientists at each the improvement and operational

laboratories as techniques are advanced and as elements that result in ability technique failures are recognized and controlled. A corporate knowledge repository is needed during the technique to ensure important records is captured that may be reviewed and introduced to withinside the future such that instructions discovered may be implemented to the particular technique below consideration and additionally to different comparable techniques being implemented to different products. Such a repository (consistent with concepts defined in the draft ICH Q10) will allow continuous development and change control of the technique to take place during its lifecycle. Rather than persevering with to carry out analytical technology transfer exercises and ICH validation, a QbD method primarily based totally on a risk-assessed change control method must be adopted. Each time a technique is changed, a risk evaluation must be done. Where the change is recognized as having a ability to take the technique outside its recognized design space, a technique assessment and, if appropriate, an equivalency exercise have to be carried out to make sure technique overall performance standards are still met. This will permit for technique enhancements to be made through internal change control procedures, or even switches among unique techniques (e.g., HPLC as opposed to NIR) may come to be a lot simpler to implement. A QbD method for analytical techniques that consists of risk evaluation, robustness checking out, and ruggedness checking out is much extra rigorous than ICH validation requirements (Q2(R1)). It additionally consists of an evaluation of technique variability as compared with the specification limits, which is one of the most vital technique attributes to test while determining whether or not the technique is suit for its purpose. The method defined herein indicates that ICH Q2(R1), even as including a few value, should be considerably rewritten to take account of the QbD risk-based approaches defined on this article.[24]

REFERENCES

1. Woodcock J, The concept of pharmaceutical quality. American Pharmaceutical Review, 7(6), 2004,.[1]
2. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006.[2]

3. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.[3]
4. Lionberger RA, Lee LS, Lee L, Raw A ,Yu LX, Quality by design: Concepts for ANDAs, The AAPS Journal, 10, 2008, 268–276.[4]
5. FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool (Draft Guidance).[5]
6. Q8 (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.[6]
7. Callis JB, Illman DL, Kowalski BR, Process analytical chemistry. Analytical Chemistry, 59, 1987, 624A–637A.[7]
8. Yu LX, Pharmaceutical quality by design: Product and process development, understanding, and control. Pharmaceutical Research, 25, 2008, 781–791.[8]
9. Munson J, Gujral B, Stanfield CF, A review of process analytical technology (PAT) in the U.S. pharmaceutical industry. Current Pharmaceutical Analysis, 2, 2006, 405–414.[9]
10. Leuenberger H, Puchkov M, Krausbauer E, Betz G, Manufacturing pharmaceutical granules, Is the granulation end-point a myth, Powder Technology, 189, 2009, 141–148.[10]
11. Miller CE, Chemometrics and NIR: A match made in heaven, Am. Pharm. Rev. Food and Drug Administration CDER, Guidance for industry, Q8 pharmaceutical development; 2:41–48, 2006.[11]
12. Nasr M. Risk-based CMC review paradigm, Advisory committee for pharmaceutical science meeting, 2004. [12,13]
13. Food and Drug Administration CDER. Guidance for industry: Immediate release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1995. [14]
14. Food and Drug Administration CDER. Guidance for industry:

Modified release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997. [15]

15. Food and Drug Administration CDER. Guidance for industry: Non sterile semisolid dosage forms scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997. [16]
16. Food and Drug Administration CDER. Guidance for industry: Changes to an approved NDA or ANDA, 2004.[17]
17. Woodcock J, The concept of pharmaceutical quality. American Pharmaceutical Review, 2004, 1–3. [18]
18. Food and Drug Administration, Office of Generic Drugs White Paper on Question-based Review: http://www.fda.gov/cder/ OGD/QbR.htm.[19,20]
19. Food and Drug Administration, Guidance for industry, Q6A specifications for new drug substances and products: Chemical substances, 1999. [21]
20. Nasr M, FDA's quality initiatives: An update, http://www.gmpcompliance.com/daten/download/FDAs_Quality_Initiative.pdf, 2007. [22]
21. IBM Business Consulting Services, Transforming industrialization: A new paradigm for pharmaceutical development, www-935.ibm.com/services/us/imc/pdf/ge 510– 3997-transforming-industrialization.pdf, 2006. [23]
22. Food and Drug Administration: http://www.fda.gov/ohrms/ dockets/ac/06/minutes/2006–4228m1.pdf, 2006. [24]
23. Zhang H, Lawrence X, Dissolution testing for solid oral drug products: Theoretical considerations, American Pharmaceutical Review, 2004, 26–31.